Prosecution Insights
Prosecution Insights
6 pending office actions • 3 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| §102 only | 1 (17%) |
| No statute on record | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ANGELL, JON E | 2 | 70.7% | +21.1% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 60.9% | +38.7% |
| ZARA, JANE J | 1 | 70.8% | +15.9% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.7% | +22.1% |
| SHIN, DANA H | 1 | 27.2% | +27.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17592182 | Methods For The Treatment Of APOC3-Related Diseases And Disorders | SHIN, DANA H | 33d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18048577 | RNAi Agents for Inhibiting Expression of Matrix Metalloproteinase 7 (MMP7), Compositions Thereof, and Methods of Use | VANHORN, ABIGAIL LOUISE | 97d overdue |
| 18178242 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | ZARA, JANE J | 31d overdue |
| 18074268 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | ANGELL, JON E | 4d overdue |
| 18181311 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | SULLIVAN, STEPHANIE LAUREN | 12d |
| 17592182 | Methods For The Treatment Of APOC3-Related Diseases And Disorders | SHIN, DANA H | 33d |
| 18026340 | METHODS FOR THE REDUCTION OF Z-AAT PROTEIN LEVELS | ANGELL, JON E | 34d |
| Art Unit | Apps |
|---|---|
| 1637 | 3 |
| 1635 | 2 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18026340 | METHODS FOR THE REDUCTION OF Z-AAT PROTEIN LEVELS | ANGELL, JON E | 1637 | §102 | Non-Final OA | 34d | Pending | Mar 14, 2023 |
| 18181311 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | SULLIVAN, STEPHANIE LAUREN | 1635 | Other | Non-Final OA | 12d | Pending | Mar 09, 2023 |
| 18178242 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | ZARA, JANE J | 1637 | Other | Non-Final OA | 31d overdue | Pending | Mar 03, 2023 |
| 18074268 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | ANGELL, JON E | 1637 | §103 | Non-Final OA | 4d overdue | Pending | Dec 02, 2022 |
| 18048577 | RNAi Agents for Inhibiting Expression of Matrix Metalloproteinase 7 (MMP7), Compositions Thereof, and Methods of Use | VANHORN, ABIGAIL LOUISE | 1636 | Other | Final Rejection | 97d overdue | Pending | Oct 21, 2022 |
| 17592182 | Methods For The Treatment Of APOC3-Related Diseases And Disorders | SHIN, DANA H | 1635 | §103 | Final Rejection | 33d | Pending | Feb 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial